BCRX vs LLY
BioCryst Pharmaceuticals, Inc. vs Eli Lilly and Company — AI-powered side-by-side comparison
BCRX
BioCryst Pharmaceuticals, Inc.
66
Buy
VS
LLY
Eli Lilly and Company
56
Buy
| Metric | BCRX | LLY |
|---|
| AI Score |
66
|
56
|
| Price |
$9.81
|
$1,238.69
|
| P/E Ratio |
-6.73×
|
41.81×
|
| ROE |
-221.4%
|
77.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
23.5%
|
84.0%
|
| Debt / Equity |
-0.90×
|
1.62×
|
| Dividend Yield |
0.0%
|
0.5%
|
| RSI (14) |
48.8
|
59.0
|
| Beta |
0.554
|
0.506
|
| Expected Upside |
+1.3%
|
+0.1%
|
AI Committee View
Current Innellis committee reasoning for BCRX versus LLY.
BCRX leads by 10 points.
BCRX scores 66/100 (Buy) versus LLY at 56/100 (Buy).
BCRX Committee View
80% agreement
5 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — quarter-over-quarter growth rate is accelerating, not just positive. Risk Analyst remains cautious — bollinger bandwidth of 18.9% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Bollinger bandwidth of 18.9% signals elevated volatility — Risk
LLY Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 49.6% yoy -- genuine top-line momentum. Risk Analyst remains cautious — high leverage (debt-to-equity 1.60) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 92.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 49.6% YoY -- genuine top-line momentum — Growth
- EPS growing 94.6% YoY — Growth
Bear Case
- P/E of 43.2 is expensive by classic value standards — Value
- Price-to-book of 38.3x prices in significant intangible value — Value
- Debt-to-equity of 1.60 adds balance-sheet risk to the value case — Value